A perioperative study of Safusidenib in patients with IDH1-mutated glioma
- Author(s)
- Cain, SA; Topp, M; Rosenthal, M; Tobler, R; Freytag, S; Best, SA; Whittle, JR; Drummond, KJ;
- Journal Title
- Future Oncology
- Abstract
- This is a single arm, open label perioperative trial to assess the feasibility, pharmacokinetics and pharmacodynamics of treatment with safusidenib following biopsy, and prior to surgical resection in patients with IDH1 mutated glioma who have not received radiation therapy or chemotherapy. Fifteen participants will receive treatment in two parts. First, biopsy followed by one cycle (28 days) of safusidenib, an orally available, small molecular inhibitor of mutated IDH1, then maximal safe resection of the tumor (Part A). Second, after recovery from surgery, safusidenib until disease progression or unacceptable toxicity (Part B). This research will enable objective measurement of biological activity of safusidenib in patients with IDH1 mutated glioma. Anti-tumor activity will be assessed by progression free survival and time to next intervention.Clinical Trial Registration: NCT05577416 (ClinicalTrials.gov).; Adult low-grade gliomas (aLGG) are primary brain cancers, defined by mutations in IDH1 or IDH2. When the IDH gene becomes abnormal (mutated), production of a metabolite that causes cancer cells to grow is increased. These tumors grow slowly but invade the normal functioning brain, making them nearly impossible to cure. The current standard of care treatment includes surgery, followed by radiation therapy and chemotherapy, the timing of which depends on the risk of cancer regrowth. Some patients may be suitable for monitoring with MRI scans alone, however recurrences will inevitably occur. Recently developed targeted mutant IDH inhibitors for aLGG patients may be beneficial both at diagnosis and recurrence. Notably, early treatment prior to radiation therapy and chemotherapy delays growth of aLGG and the need for subsequent radiation therapy and chemotherapy. Nevertheless, most patients will eventually suffer further tumor growth and the optimal timing and sequencing of these therapies remains an area of active research. This research investigates the mutant IDH1 inhibitor safusidenib. The researchers are conducting an innovative clinical trial where patients with aLGG, who have not received radiation therapy or chemotherapy, are treated with safusidenib following a biopsy and prior to surgical removal of their tumor. In this study they investigate whether this trial design is safe and feasible, and how safusidenib works; with the goal to better understand the optimal use of IDH inhibitors for patients with aLGG.; eng
- Publisher
- Taylor & Frances
- Keywords
- Ab-218; Idh1; Phase 0; isocitrate dehydrogenase 1; low grade glioma; safusidenib; window of opportunity
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 39140289
- Publisher's Version
- https://doi.org/10.1080/14796694.2024.2383064
- Open Access at Publisher's Site
https://doi.org/10.1080/14796694.2024.2383064- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-23 02:54:19
Last Modified: 2024-08-23 02:56:30